Cantor Fitzgerald Reiterates Overweight on Soleno Therapeutics, Maintains $19 Price Target
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Kristen Kluska has reiterated an Overweight rating on Soleno Therapeutics (NASDAQ:SLNO) and maintained a $19 price target.
August 31, 2023 | 2:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated an Overweight rating on Soleno Therapeutics and maintained a $19 price target.
The reiteration of an Overweight rating by Cantor Fitzgerald indicates a positive outlook for Soleno Therapeutics. The maintained price target of $19 suggests that the analyst believes the stock is undervalued at current levels, which could lead to upward price movement in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100